Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

11 Apr 2023

New Study Treats Teenagers With Ketamine Therapy, Shows Promising Results

From successful clinical trials using ketamine for alcohol-use disorder, to the countless patients benefiting from treatments at ketamine clinics and at-home delivery services — ketamine-assisted psychotherapy is gaining acceptance as...

By Jason Najum

Health & Wellness

6 Apr 2023

Interview: Veteran Shares How Ketamine Clinic Closings Hurt Patients

Adam Blazak, a US Army veteran, was receiving ketamine treatments for mental health issues. The treatments were working – until Ketamine Wellness Centers suddenly closed operations and left him without...

By Jason Najum

Health & Wellness

24 Mar 2023

Ketamine Patients Suffer From Clinic Closings, Telehealth Rules

This week I received an email from a veteran, sharing how the closure of ketamine clinics came as a terrible surprise and that he doesn't know how he'll be able...

By Jason Najum

Industry

17 Mar 2023

Irwin Naturals Backs Out of Deal To Buy Braxia Scientific

Irwin Naturals has backed out of the deal to buy Braxia, terminating the non-binding agreement and Letter of Intent....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

13 Mar 2023

Ketamine Wellness Centers Closes Its Operations

Ketamine Wellness Centers, one of the largest ketamine therapy providers in the US, has closed its operations....

By Jason Najum

Industry

6 Mar 2023

atai Life Sciences Announces Clinical Pipeline and Corporate Updates

Today we got some clarity as atai Life Sciences released a pipeline update....

By Jason Najum

Industry

1 Mar 2023

Investing in Psychedelic Therapy Real Estate with Healing REIT

We sat down with the team at Healing REIT to discuss the challenges of finding suitable properties for psychedelic therapy and how real estate infrastructure will play a critical role...

By Jason Najum

Healing

21 Feb 2023

My First Ketamine Therapy Experience

What I remember most is the music. Psychedelic experiences tend to leave you with fragments — pieces of floating integration waiting to be more fully absorbed — and for my...

By Jason Najum

Science

17 Feb 2023

New Study Shows SSRIs Ineffective Compared to Psychedelics

New Study Shows SSRIs Ineffective vs Psychedelics....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.